Recursion Pharmaceuticals Stock

recursionpharma.comBioTechFounded: 2013Funding to Date: $333.7MM

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.

Register for Details

For more details on financing and valuation for Recursion Pharmaceuticals, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Christopher Gibson Ph.D
Co-Founder, Chief Executive Officer & Board Member
Tina Larson
Chief Operating Officer
Mason Victors
Chief Technology Officer & Chief Product Officer
Sharath Hegde
Chief Scientific Officer
Kevin Leggat
Controller
Ben Sukow
Director, Engineering
Ronald Alfa Ph.D
Senior Vice President of Translational Discovery & Chief Evangelist
Kevin Lynch Ph.D
Chief Business Officer
Heather Kirkby
Chief People Officer
Dean Li Ph.D
Board Member & Founder
Blake Borgeson Ph.D
Co-Founder, Scientific Advisor & Board Member

Board Members

Alaa Halawa
Mubadala Investment Company
Blake Borgeson Ph.D
Christopher Gibson Ph.D
Dean Li Ph.D
James Hardiman
Data Collective
Nan Li
Obvious Ventures
Perry Fell Ph.D
Reid Hutchins
Advantage Capital (Saint Louis)
Zachary Bogue JD
Data Collective
Zavain Dar
Lux Capital Management

Other companies like Recursion Pharmaceuticals in the BioTech sector

Sector
Last Round Est. Valuation
$143.8MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$138.75MM
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$289.42MM
Sector
Last Round Est. Valuation
$1.08B

News

The new investment provides Recursion with capital to further develop its drug discovery platform and pipeline.